Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning.

Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL.

J Cell Biol. 2006 Apr 24;173(2):279-89.

2.

Hamartin and tuberin: working together for tumour suppression.

Jozwiak J.

Int J Cancer. 2006 Jan 1;118(1):1-5. Review.

3.

Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M.

Neuromolecular Med. 2005;7(4):287-96. Review.

PMID:
16391386
4.

The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.

Rosner M, Hanneder M, Siegel N, Valli A, Hengstschläger M.

Mutat Res. 2008 Mar-Apr;658(3):234-46. doi: 10.1016/j.mrrev.2008.01.001. Epub 2008 Jan 12. Review.

PMID:
18291711
5.

Tumour suppressors hamartin and tuberin: intracellular signalling.

Krymskaya VP.

Cell Signal. 2003 Aug;15(8):729-39. Review.

PMID:
12781866
6.

The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.

Nobukini T, Thomas G.

Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Review.

PMID:
15562827
7.

Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.

Astrinidis A, Henske EP.

Oncogene. 2005 Nov 14;24(50):7475-81. Review.

PMID:
16288294
8.

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Kwiatkowski DJ, Manning BD.

Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. Review.

PMID:
16244323

Supplemental Content

Support Center